FDA Faces Pressure to Reverse Peptide Safety Restrictions Under Kennedy Leadership
Key Insights
The FDA is poised to reverse its 2023 decision categorizing 19 peptides (search) as too unsafe for compounding pharmacies under HHS Secretary Robert F. Kennedy Jr., who called the original ban "illegal."
Former FDA officials dispute Kennedy's characterization, stating the 2023 decision was supported by documented safety concerns including immune reactions, adverse events, and deaths in clinical studies.
The compounding pharmacy industry argues peptides (search) would be safer dispensed by regulated pharmacies than through the current gray market, despite limited clinical data supporting their safety or effectiveness.
The Food and Drug Administration is preparing to reverse course on peptide regulations under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., potentially opening access to 19 peptide compounds that the agency deemed too unsafe for compounding pharmacies just three years ago.
In February, Kennedy characterized the FDA's 2023 decision to categorize these peptides (search) as unsafe as "illegal," arguing on "The Joe Rogan Experience" podcast that the agency lacked proper safety signals to justify the restrictions. "They're not supposed to do that unless there's a safety signal," Kennedy said. "And they didn't have a safety signal. They're not allowed to look at efficacy."
However, three former FDA officials closely involved in the original peptide evaluation process strongly dispute Kennedy's characterization. They maintain that the 2023 decision was supported by numerous documented safety concerns and that FDA regulations require assessment of both safety and effectiveness before approving substances for compounding.
Safety Concerns Drive Original Restrictions
The FDA's 2023 decision to place 19 peptides (search) in Category 2 - substances considered too risky for compounding - was based on well-established research showing that injectable peptides carry significant risks of immune reactions. These reactions can range from mild responses to life-threatening anaphylactic shock (search) that constricts breathing and impairs motor function.
The agency's review found limited human studies on most peptides (search), with data primarily from animal studies or specific clinical populations like HIV patients. Where human data existed, it indicated potential for harm. Subjects in studies of six individual peptides - growth hormone releasing peptide-2 (search), ibutamoren mesylate, ipamorelin, CJC-1295, AOD-9604 and melanotan II - experienced adverse events, including death, though causation wasn't definitively established.
"Of course any adverse event can be a flag," said a former FDA official who worked in the compounding division during the peptide categorization. "Also, if there is no clinical data for a substance, and an awareness that the substance has the propensity for harm, that could make it an appropriate placement on the Category 2 list."
Market Demand Drives Regulatory Pressure
Despite regulatory restrictions, demand for peptides (search) has exploded as social media influencers promote promises of enhanced physiques, anti-aging benefits, and improved sexual function. This demand has created a burgeoning gray market where wellness spas, multilevel marketers, and telehealth websites sell "research grade" peptides labeled "not for human use."
The disconnect between regulatory structure and market demand is driving the current push to reclassify peptides (search) from Category 2 to Category 1, where the FDA exercises enforcement discretion. This reclassification process is already occurring, with the FDA actively reviewing peptide nominations and, in some cases, removing substances from Category 2 for potential inclusion on the 503A bulks list.
Industry Arguments for Regulatory Change
The Alliance for Pharmacy Compounding (search), representing the industry's largest lobbying effort, acknowledges limited knowledge about individual peptide safety but argues the public would be safer with regulated compounding pharmacies handling these substances rather than the gray market.
"Where we don't have research, clinical trials, what we've got a ton of, is, shall we say, testimonials, patient affidavits, attesting to the wonders of the drug," said Scott Brunner, the alliance's chief executive officer. "And RFK Jr. is one of those testifiers."
The organization contends that peptides (search) dispensed by regulated compounders would use active ingredients manufactured at FDA-registered facilities and be prepared under sterile conditions overseen by state pharmacy boards - "a heck of a lot better than what many consumers are doing," according to Brunner.
Advisory Committee Maintains Safety Stance
In the final months of the Biden administration, an FDA advisory committee reviewed six peptides (search) that had been fast-tracked for evaluation following industry lawsuits. Despite industry presentations offering anecdotal evidence of safety, the committee sided with the FDA's recommendation against adding these peptides to the approved bulks list.
The peptides (search) under review - CJC-1295, AOD-9604, thymosin-alpha (search), ipamorelin acetate, kisspeptin, and ibutamoren mesylate - are marketed online for weight loss, muscle-building, anti-aging, insomnia, tissue repair, and sexual dysfunction.
Regulatory Pathways Forward
Kennedy has indicated plans for "some kind of action" to make "about 14" peptides (search) "more accessible," though he hasn't specified which compounds or the exact mechanism. Several regulatory shortcuts exist, including removing peptides from Category 2, placing them in Category 1, or announcing changed enforcement strategies.
Former FDA acting commissioner Janet Woodcock warns that such shortcuts would undermine decades of drug safety standards. "It would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S.," she said.
The FDA recently reinforced strict conditions for compounding exemptions under Sections 503A and 503B, emphasizing that compounded drugs must be tied to patient-specific prescriptions and cannot be essentially copies of commercially available drugs. The agency specified that adding ingredients like vitamin B12 to semaglutide would not avoid "copy" status if the formulation remains functionally substitutable.
As the regulatory landscape shifts, compounding pharmacies face the challenge of navigating between market opportunities and federal compliance, with the ultimate resolution likely to reshape access to peptide therapies across the healthcare system.